- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05440409
CAR-Multicenter Analyse (CAR-MA): retrospectieve studie om CAR T-celuitkomsten en gerelateerde toxiciteiten bij kinderen en jongvolwassenen met B-ALL te karakteriseren
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
To evaluate the response of extramedullary disease following CAR T-cell therapy.
To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
- To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
- To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
- To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
- To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
- To evaluate the response of extramedullary disease following CAR T-cell therapy.
- To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
- To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
- To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
- To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
- To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20892
- National Cancer Institute (NCI)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.
Beschrijving
- Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: RETROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
1
Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Response free survival (completed)
Tijdsspanne: 6 months
|
To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. |
6 months
|
|
Outcome evaluation
Tijdsspanne: 12 months
|
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL |
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Complete Response Rate (completed)
Tijdsspanne: 12 months
|
To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Relapse Rate (completed)
Tijdsspanne: 12 months
|
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Response free survival (completed)
Tijdsspanne: 12 months
|
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Minimal Residual Disease detection (completed)
Tijdsspanne: 12 months
|
To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Impact of immunotherapies on CAR outcomes
Tijdsspanne: 12 months
|
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes |
12 months
|
|
Cytopenias after CAR
Tijdsspanne: 12 months
|
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes |
12 months
|
|
Response of extramedullary disease
Tijdsspanne: 12 months
|
To evlauate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Frequency of malignant neoplasms
Tijdsspanne: 12 months
|
To evaluate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Response, survival and toxicities in subpopulations
Tijdsspanne: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations. |
12 months
|
|
Impact of next generation sequencing MRD and duration of B cell aplasia
Tijdsspanne: 12 months
|
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes. |
12 months
|
|
Frequency of infections
Tijdsspanne: 12 months
|
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy. |
12 months
|
|
Response, survival and toxicities after CAR
Tijdsspanne: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy) |
12 months
|
|
Compare toxicities and outcomes across CAR constructs
Tijdsspanne: 12 months
|
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.) |
12 months
|
|
Impact of CAR on other health-related outcomes
Tijdsspanne: 12 months
|
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes |
12 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Sara K Silbert, M.D., National Cancer Institute (NCI)
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Ziekte attributen
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, Lymfoïde
- Leukemie
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Herhaling
- Voorlopercel lymfoblastische leukemie-lymfoom
Andere studie-ID-nummers
- 10000651
- 000651-C
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All IPD recorded in the medical record will be shared with intramural investigators upon request.
IPD-tijdsbestek voor delen
Clinical data available during the study and indefinitely.
IPD-toegangscriteria voor delen
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .